医疗产品

Search documents
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 22:10
Financial Performance - Quanterix Corporation reported a quarterly loss of $0.53 per share, better than the Zacks Consensus Estimate of a loss of $0.69, but worse than a loss of $0.26 per share a year ago, indicating an earnings surprise of 23.19% [1] - The company posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%, although this is a decline from year-ago revenues of $32.07 million [2] - Over the last four quarters, Quanterix has surpassed consensus revenue estimates three times [2] Stock Performance - Quanterix shares have declined approximately 50.3% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $30.83 million, and for the current fiscal year, it is -$1.62 on revenues of $138.32 million [7] Industry Outlook - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quanterix's stock performance [5]
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
ZACKS· 2025-05-12 12:45
Company Performance - OrganiGram reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, representing an earnings surprise of -333.33% [1] - The company posted revenues of $29.76 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 29.59%, compared to revenues of $27.91 million a year ago [2] - Over the last four quarters, OrganiGram has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Outlook - OrganiGram shares have declined approximately 26.7% since the beginning of the year, while the S&P 500 has decreased by -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $45.73 million, and for the current fiscal year, it is -$0.16 on revenues of $166.74 million [7] - The estimate revisions trend for OrganiGram is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently in the bottom 33% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact OrganiGram's stock performance [5]
ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
ZACKS· 2025-05-08 23:50
Company Performance - ICU Medical reported quarterly earnings of $1.72 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and up from $0.96 per share a year ago, representing an earnings surprise of 39.84% [1] - The company posted revenues of $599.49 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.54%, compared to $566.66 million in the same quarter last year [2] - Over the last four quarters, ICU Medical has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - ICU Medical shares have declined approximately 13.3% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The current Zacks Rank for ICU Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.66 on revenues of $569.35 million, and for the current fiscal year, it is $6.90 on revenues of $2.28 billion [7] - The outlook for the medical products industry is currently in the bottom 32% of over 250 Zacks industries, which may impact the stock's performance [8]
VAREX IMAGING (VREX) Q2 Earnings and Revenues Beat Estimates
ZACKS· 2025-05-08 23:20
Company Performance - VAREX IMAGING reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and up from $0.16 per share a year ago, representing an earnings surprise of 85.71% [1] - The company posted revenues of $212.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.93%, compared to year-ago revenues of $206.2 million [2] - Over the last four quarters, VAREX IMAGING has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - VAREX IMAGING shares have declined approximately 44% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $207.93 million, and for the current fiscal year, it is $0.54 on revenues of $824.37 million [7] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact VAREX IMAGING's stock performance [5][6]
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates
ZACKS· 2025-05-08 22:25
Company Performance - BioLife Solutions, Inc. reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company achieved revenues of $23.94 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.28%, although this represents a decline from year-ago revenues of $31.73 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS estimates [2] Stock Performance - BioLife Solutions shares have declined approximately 17.8% since the beginning of the year, in contrast to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $23.29 million, and for the current fiscal year, it is -$0.09 on revenues of $97.18 million [7] Industry Outlook - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of BioLife Solutions may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates
ZACKS· 2025-05-08 22:20
Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...
InfuSystems Holdings, Inc. (INFU) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-08 12:50
InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company ...
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
ZACKS· 2025-05-07 23:55
Core Insights - Evolus, Inc. reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -80% [1] - The company's revenues for the quarter ended March 2025 were $68.52 million, missing the Zacks Consensus Estimate by 4.83%, but showing an increase from $59.33 million year-over-year [2] - Evolus has not surpassed consensus EPS estimates over the last four quarters and has only topped revenue estimates once in that same period [2] Company Performance - Evolus shares have increased by approximately 5.2% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $82.86 million, and for the current fiscal year, it is -$0.01 on revenues of $351.43 million [7] Earnings Outlook - The estimate revisions trend for Evolus is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The outlook for the Medical - Products industry, to which Evolus belongs, is in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8]
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-07 23:30
Company Performance - Myomo, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.10 per share a year ago [1] - The company posted revenues of $9.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.29%, compared to revenues of $3.75 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Stock Outlook - Myomo shares have declined approximately 25.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $10.35 million, and for the current fiscal year, it is -$0.07 on revenues of $50.95 million [7] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myomo's stock performance [5][6]
Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates
ZACKS· 2025-05-07 22:41
Company Performance - Biote Corp. reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, but down from $0.23 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $48.99 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.51%, compared to $46.8 million in the same quarter last year [2] - Biote Corp. has surpassed consensus EPS estimates in all four of the last quarters, but has only topped consensus revenue estimates once during the same period [2] Stock Performance - Biote Corp. shares have declined approximately 45.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current Zacks Rank for Biote Corp. is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $50.2 million, and for the current fiscal year, it is $0.39 on revenues of $205.41 million [7] - The outlook for the Medical - Products industry, to which Biote Corp. belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]